drugset / Trial / NCT06333171

4-aminopyridine for Skin Wound Healing

NCT06333171

Phase 2 Recruiting 150 enrolled John Elfar
RandomizedParallel-groupDouble-blindTreatment

Summary

Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults. The purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing. The investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.

Timeline

Start
2025-09
Primary completion
2027-09
Completion
2028-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dalfampridine Small molecule 10 mg Oral

Indications

No indication recorded.